Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
17.77 MXN -4.51% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +6.53% +25.49%
Apr. 25 Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
Apr. 24 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

Number of employees: 1,590

Sales per Business

MXN in Million2022Weight2023Weight Delta
Pharmaceutical Products and Personal Care Products
100.0 %
16,820 100.0 % 16,467 100.0 % -2.10%

Sales per region

MXN in Million2022Weight2023Weight Delta
International
51.2 %
10,069 59.9 % 8,431 51.2 % -16.27%
Mexico
48.8 %
6,751 40.1 % 8,037 48.8 % +19.05%

Managers

Managers TitleAgeSince
Marco Sparvieri CEO
 Chief Executive Officer - -
Rodrigo Alonso Herrera Aspra FOU
 Founder - 96-10-29
Antonio Zamora Galland DFI
 Director of Finance/CFO - -
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 18-09-09
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 12-03-28
Alejandro Bastón Patiño IRO
 Public Communications Contact - 08-09-30

Members of the board

Members of the board TitleAgeSince
Burkhard Wittek BRD
 Director/Board Member 70 18-04-17
Rodrigo Alonso Herrera Aspra FOU
 Founder - 96-10-29
Sabrina Lucila Herrera Aspra BRD
 Director/Board Member - 97-12-31
Jorge Ricardo Gutiérrez Muñoz BRD
 Director/Board Member 80 -
Juan Alonso BRD
 Director/Board Member - -
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 12-03-28
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 18-09-09
Carlos Javier Vara Alonso BRD
 Director/Board Member - 18-04-17
Javier Vale Castilla BRD
 Director/Board Member - -
Ignacio Gonzalez Rodriguez BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,020,000,000 712,097,600 ( 69.81 %) 74,855,920 ( 7.339 %) 69.81 %

Shareholders

NameEquities%Valuation
Rodrigo Alonso Herrera Aspra
30.38 %
309,876,000 30.38 % 304 M $
MFS International (UK) Ltd.
2.504 %
25,535,784 2.504 % 25 M $
Skagen AS (Investment Management)
2.451 %
25,000,471 2.451 % 25 M $
Lemanik Asset Management SA
1.555 %
15,863,042 1.555 % 16 M $
BlackRock México Operadora SA de CV SOFI
1.370 %
13,976,395 1.370 % 14 M $
Operadora de Fondos Banorte SA de CV
1.166 %
11,896,415 1.166 % 12 M $
North of South Capital LLP
1.021 %
10,418,796 1.021 % 10 M $
Sabrina Lucila Herrera Aspra
1.000 %
10,200,000 1.000 % 10 M $
Marco Francisco Forastieri Muñoz
0.9375 %
9,562,500 0.9375 % 9 M $
Denker Capital (Pty) Ltd.
0.8247 %
8,412,284 0.8247 % 8 M $

Company contact information

Genomma Lab Internacional SAB de CV

Avendia Antonio Dovalí Jaime, 70 Torre C, Piso 2, Despacho A

01210, Mexico City

+

http://www.genommalab.com
address Genomma Lab Internacional, S.A.B. de C.V.(LAB B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
17.77 MXN
Average target price
19.46 MXN
Spread / Average Target
+9.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+25.49% 1.03B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Company Genomma Lab Internacional, S.A.B. de C.V.